MedTrace Logo

Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients

NCT01528800 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2021-06-28

No results posted yet for this study

Summary

The purpose of this study is to see if vitamin K supplementation three times per week reduces the progression of coronary artery calcification over 12 months in dialysis patients compared to placebo.

Conditions

  • End-stage Kidney Disease

Interventions

DRUG

Vitamin K1

10mg orally three times a week for 12 months

DRUG

Microcrystalline Methylcellulose

10mg orally three times a week for 12 months

Sponsors & Collaborators

  • Dr. Rachel Holden

    lead OTHER

Principal Investigators

  • Rachel Holden · Queens University/Kingston Health Sciences Centre: Kingston General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01528800 on ClinicalTrials.gov